R Tian1, N Musi, J D'Agostino, M F Hirshman, L J Goodyear. 1. NMR Laboratory for Physiological Chemistry, Division of Cardiovascular Medicine, Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. rtian@rics.bwh.harvard.edu
Abstract
BACKGROUND: Recent reports suggest that activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), in response to acute changes in cellular energy status in cardiac and skeletal muscles, results in altered substrate utilization. We hypothesized that chronic alterations in myocardial energetics in hypertrophied hearts (left ventricular hypertrophy, LVH) will lead to elevated AMPK activity, which in turn regulates substrate utilization. METHODS AND RESULTS: Using (31)P NMR spectroscopy and biochemical assays, we found that in LVH hearts, adenosine triphosphate (ATP) concentration decreased by 10%, phosphocreatine concentration decreased by 30%, and total creatine concentration was unchanged. Thus, the ratio of phosphocreatine/creatine decreased to one third of controls, and the ratio of AMP/ATP increased to 5 times above controls. These changes were associated with increased alpha(1) and alpha(2) AMPK activity (3.5- and 4.8-fold above controls, respectively). The increase in AMPK alpha(1) activity was accompanied by a 2-fold increase in alpha(1) expression, whereas alpha(2) expression was decreased by 30% in LVH. The basal rate of 2-deoxyglucose uptake increased by 3-fold in LVH, which was associated with an increased amount of glucose transporters present on the plasma membrane. CONCLUSIONS: These results demonstrate for the first time that chronic changes in myocardial energetics in hypertrophied hearts are accompanied by significant elevations in AMPK activity and isoform-specific alterations in AMPK expression. It also raises the possibility that AMPK signaling plays an important role in regulating substrate utilization in hypertrophied hearts.
BACKGROUND: Recent reports suggest that activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK), in response to acute changes in cellular energy status in cardiac and skeletal muscles, results in altered substrate utilization. We hypothesized that chronic alterations in myocardial energetics in hypertrophied hearts (left ventricular hypertrophy, LVH) will lead to elevated AMPK activity, which in turn regulates substrate utilization. METHODS AND RESULTS: Using (31)P NMR spectroscopy and biochemical assays, we found that in LVH hearts, adenosine triphosphate (ATP) concentration decreased by 10%, phosphocreatine concentration decreased by 30%, and total creatine concentration was unchanged. Thus, the ratio of phosphocreatine/creatine decreased to one third of controls, and the ratio of AMP/ATP increased to 5 times above controls. These changes were associated with increased alpha(1) and alpha(2) AMPK activity (3.5- and 4.8-fold above controls, respectively). The increase in AMPK alpha(1) activity was accompanied by a 2-fold increase in alpha(1) expression, whereas alpha(2) expression was decreased by 30% in LVH. The basal rate of 2-deoxyglucose uptake increased by 3-fold in LVH, which was associated with an increased amount of glucose transporters present on the plasma membrane. CONCLUSIONS: These results demonstrate for the first time that chronic changes in myocardial energetics in hypertrophied hearts are accompanied by significant elevations in AMPK activity and isoform-specific alterations in AMPK expression. It also raises the possibility that AMPK signaling plays an important role in regulating substrate utilization in hypertrophied hearts.
Authors: Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade Journal: Eur J Heart Fail Date: 2012-02 Impact factor: 15.534
Authors: Evelin Seppet; Margus Eimre; Nadezhda Peet; Kalju Paju; Ehte Orlova; Mati Ress; Sirje Kõvask; Andres Piirsoo; Valdur A Saks; Frank N Gellerich; Stephan Zierz; Enn K Seppet Journal: Mol Cell Biochem Date: 2005-02 Impact factor: 3.396
Authors: Eric J Jaehnig; Analeah B Heidt; Stephanie B Greene; Ivo Cornelissen; Brian L Black Journal: Mol Cell Biol Date: 2006-10-09 Impact factor: 4.272
Authors: Yoni Athéa; Benoît Viollet; Philippe Mateo; Delphine Rousseau; Marta Novotova; Anne Garnier; Sophie Vaulont; James R Wilding; Alain Grynberg; Vladimir Veksler; Jacqueline Hoerter; Renée Ventura-Clapier Journal: Diabetes Date: 2007-03 Impact factor: 9.461
Authors: Jonathan C Schisler; Carrie E Rubel; Chunlian Zhang; Pamela Lockyer; Douglas M Cyr; Cam Patterson Journal: J Clin Invest Date: 2013-07-25 Impact factor: 14.808